Clinical Trials Browser

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03231306 2025-05-02

NF108-BINI

Phase 2 Completed

45 enrolled 8 charts

CNS

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

NCT02332902 2023-12-20

DCLNF1

Phase 2 Completed

24 enrolled 4 charts

CNS

Neurofibroma, Neurofibromatosis 1

NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Phase 2 Completed

9 enrolled 9 charts

CNS

Neurofibroma, Neurofibromatosis 1

NCT01347307 2020-06-18

Stereotactic Body Radiotherapy for Spine Tumors

Phase NA Completed

38 enrolled 11 charts

CNSEndocrineSarcoma

Arteriovenous Malformations, Chordoma, Meningioma, Neurilemmoma, Neurofibroma, Paraganglioma

NCT02096471 2019-01-10

MEK Inhibitor

Phase 2 Completed

19 enrolled 14 charts

CNS

Neurofibroma, Neurofibromatosis 1

NCT00021541 2018-04-17

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Phase 2 Completed

62 enrolled 13 charts

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT01275586 2017-04-12

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Phase EARLY_PHASE1 Completed

6 enrolled 7 charts

CNS

Neurofibroma, Neurofibromatoses, Neurofibroma, Plexiform

Clinical Trials

ReNeu

NF108-BINI

DCLNF1

Medical Treatment of "High-Risk" Neurofibromas

Stereotactic Body Radiotherapy for Spine Tumors

MEK Inhibitor

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas